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1. Introduction
The treatment of a number of diseases can be achieved through gene addition therapy,
where curative transgenes are established within the patient’s cells after delivery with viral
or non-viral vectors. The defective cells requiring treatment are typically differentiated;
these cells or their progenitors can be targeted for therapeutic gene transfer. However, as the
abundance of progenitor cells varies between different tissues and in the same tissue during
the fetal, neonatal and adult stages of development, the scarcity of a particular progenitor
cell pool, the paucity of spontaneous departures of progenitor cells down differentiation
pathways and unclear differentiation induction conditions can complicate genetic therapeu‐
tic intervention via these cells. Nevertheless, gene transfer to progenitor cells can be a pre‐
ferred option when differentiated cells are either poorly accessible for the vector or, once
differentiated, are defective beyond repair by gene therapy. Genetic conditions with consid‐
erable value in therapeutic gene transfer to progenitor cells include cystic fibrosis (CF) and
severe combined immunodeficiency (SCID).
The delivered transgenes can integrate into the chromosomal DNA, replicate episomally or
persist as non-replicating episomal elements in non-dividing cells. Depending on the prop‐
erties of the transgene expression cassette, particular features of specific transgene integra‐
tion sites and the state of the individual recipient cells, the transgenes are expressed with
varying degree of efficiency. On some occasions, the transgenes are permanently silenced
immediately after introduction, on other occasions transgene silencing occurs only after a
certain period of adequate expression and on still other occasions transgene expression var‐
ies dramatically among the individual clones of transgene-harbouring cells. Such variation
is thought to be mainly due to the transgene’s interaction with its immediate genetic neigh‐
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bourhood within the host genome; a phenomenon, which is similar to ‘position effect varie‐
gation’ in normal development caused by spontaneous clone-wise silencing of some
resident genes [1]. Typical position effect variegation is epigenetic instability and should be
distinguished from variegation due to somatic mutations, e.g. due to variations in the length
of polynucleotide repeat expansions [2] or due to the sorting of mitochondrial genomes in
mitochondrial heteroplasmia [3]. The element of randomness, which is inherently present in
position effect variegation, should not come as a surprise. In fact, stochastic fluctuations of
gene expression are typical both at the level of variation between different cells of tissue and
at the level of temporal variation within one cell. Both of these modes of variation are essen‐
tial for normal differentiation and tissue-patterning with the input of stochastic variation be‐
ing decisive when a developmental signal is present at a near-critical level. For the gene
therapist, it is important that the permanent silencing of transgene expression can occur
both in postmitotic target cells and target cells undergoing clonal expansion, while variega‐
tion is typically associated with clones of dividing cells. Stable long-term transgene expres‐
sion in differentiating cells is particularly challenging. In fact, the introduced genes are
subject to the pre-existing and developing gene expression patterns in the target cells, which
can override the signals from the transgenes’ own regulatory elements and, thus, can cause
transgene expression shutdown. Indeed, at a transcriptional level, the changing scenery of
transcription initiation factor pools, chromatin re-modelling and DNA methylation events
during differentiation contribute to the transiency of transgene expression.
Genomes in general and, in particular, mammalian genomes have a mosaic organisation
with functionally related genetic elements often being in close physical proximity. There are
three teleological reasons for this: 1) expediency of genetic exchange; 2) straightforward
temporal control of gene expression; 3) economy of energy, enzymes and other factors serv‐
ing the genetic elements. The second and the third of these reasons are also sufficient for the
existence of a finely patterned 3D-arrangement of DNA in interphase nuclei, simplifying the
functional interactions between distant genetic elements, e.g. interactions regulating gene
expression. It is intriguing to propose that the need to orchestrate gene expression in time
and the economy need are also driving the astonishing interconnectedness of all gene silenc‐
ing mechanisms, which we shall address in this chapter.
The gene therapist should take advantage of the pre-existing regulatory moduli present in
the target cells and should also supply the transgenes with their own expression control ele‐
ments. The regulatory elements required for reliable, long-term and tissue-specific transgene
expression include minimal promoters, enhancers, regulatory introns and locus control re‐
gions. The functional arrangement of all these elements is ultimately achieved in 3D. This
should be borne in mind, when 2D assemblies of regulatory elements are called ‘promoters’.
Some ‘promoters’ are, in fact, motley artificial chimeras. For example, a fusion between a hu‐
man cytomegalovirus (CMV) immediate-early enhancer and chicken beta-actin promoter,
exon1 and intron1 is called ‘CBA promoter’ or ‘CAG promoter’ [4].
In general, in the majority of situations in gene therapy, transgene silencing and variegation
are undesirable. We review here different factors, both host-dependent and vector-depend‐
ent, which are known to contribute to silencing and variegation of transgene expression and
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which should be taken into account where choosing or designing effective gene therapy vec‐
tors and strategies for their administration.
2. Host genetic factors of silencing and position effect variegation
Patterns for maintaining gene repression or activation are governed by regulatory machi‐
nery acting at multiple levels: 1) transcription; 2) mRNA processing, export from the nu‐
cleus, translation and degradation; 3) protein folding, modification, transport and
degradation. Control of gene expression is well-coordinated and highly hierarchical, with
the control of transcription initiation situated at the top of the regulatory ladder. A number
of interacting instruments of transcriptional gene activation and silencing in mammals are
known: DNA methylation (e.g. methylation within CpG-islands of promoters), amino acid
sequence variants of histones, covalent modifications of histones, histone-binding proteins
(e.g. powerful inhibitors of gene activity from the Polycomb Group) and combinations of
transcription initiation factors specific for particular tissues and developmental stages. The
pivotal point is the access of the transcription machinery to DNA, which is regulated via
DNA methylation and chromatin remodelling. With some simplification, it can be general‐
ized that ‘coarse tuning’ of gene expression (e.g. long-term silencing) is provided by DNA
methylation, ‘medium tuning’ is provided by chromatin remodelling and ‘fine tuning’ is
achieved via various transcription factors and a multitude of other regulatory devices.
The various branches of the regulatory machinery play their own particular roles and yet
are inherently interconnected. As detailed below, a prime example of this is the deep in‐
volvement of the miRNA pathway both in mRNA degradation and in the establishment of
chromatin methylation patterns [5].
2.1. The role of DNA methylation in silencing
DNA methylation is an important epigenetic mark involved in cell differentiation and or‐
gan and tissue development,  which plays a crucial role in the establishment of genomic
imprinting  (parent-dependent  silencing  of  alternative  alleles)  in  both  male  and  female
germ  lines.  However,  in  gene  transfer  experiments,  the  methylation  of  transgenes  was
shown to be just one ingredient in the dynamic interplay of various factors responsible for
silencing and variegation [6].
De-novo methylation patterns in humans are established mainly on implantation and in ga‐
metogenesis. Two DNA (cytosine-5)-methyltransferases, DNMT3A and DNMT3B, play an
essential role in de-novo methylation while DNMT3A in cooperation with the auxiliary pro‐
tein DNMT3L is responsible for imprinting. There is still much we do not know about the
manner in which the inactive state of the imprinted chromosomal domains is achieved and
what factors trigger this type of silencing. The available evidence indicates that ‘Smc hinge
proteins’ can be particularly important in epigenetic silencing [7]. Thus, in studies based on
X-linked GFP transgene silencing, the SmcHD1 gene was shown to play a critical role in X-
chromosome inactivation in mammals [8,9]. The recruitment of SmcHD1 to the X-chromo‐
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some may involve the non-coding Xist RNA, proteins from the Polycomb group and DNA
methyltransferases [7].
An area of intriguing research is the relationship between DNA hypermethylation and the
function of locus control regions (LCRs), controlling the local state of chromatin [10,11].
2.2. The role of histone variants and histone modifications in silencing
There are two types of structural variations among histone molecules. Firstly, there are low
abundance species of histones with unusual amino acid sequences, so-called histone var‐
iants. Secondly, histones are amenable to standard covalent protein modifications such as
acetylations and methylations of specific amino acid residues. Both structural variations are
known to play important roles in the regulation of gene expression activity.
Regions of constitutive heterochromatin are particularly prone to encroaching on the trans‐
gene in a variable pattern in different cells and, thus, to interfering with transgene expres‐
sion. Different loci in human chromosomes have a variable tendency to become involved in
heterochromatin structures. For example, chromosomes’ centromeres and telomeres are typ‐
ical regions of heterochromatin, which are known to expand occasionally, inducing steady
or intermittent silencing. In the case of centromeres, the silencing machinery might involve
the histone variant CENP-A, which is found exclusively in centromeres. Other histone var‐
iants could also play a role in silencing. Thus, the histone variant macroH2A appears to be
important in gene silencing on the inactive X-chromosome. In contrast, the histone variants
H2A.Z and H3.3 are known to be conducive for transcription.
DNA methylation and histone modifications are closely linked to chromatin remodelling
and are often jointly implicated in gene silencing and position effect variegation. Using an in
vivo mammalian model for position effect variegation, Hiragami-Hamada and co-workers
[12] extensively investigated the molecular basis for the stability of heterochromatin-mediat‐
ed silencing in mammals. Comparison between two transgenic lines, containing different
numbers of copies of human CD2 transgenes integrated within or close to a block of the per‐
icentric heterochromatin, revealed that the variegation of CD2 expression is indeed associat‐
ed with both genomic DNA methylation and histone modifications such as H3K9me3.
However, DNA methylation was the key modification that accompanied the formation of an
inaccessible chromatin structure and more stable gene silencing [12,13].
2.3. Silencing mediated by Polycomb proteins
Silencing can be mediated by proteins from the Polycomb group (PcG). These proteins can
form giant complexes, which are tethered to histones and regulatory DNA sequences called
Polycomb Response Elements (PREs). When the PcG proteins bind histones, they suppress
all the gene expression activity in the respective area of chromatin. In mammals, PcG pro‐
teins are known to be involved in cell differentiation and tissue formation and also to con‐
tribute to tumorigenesis, genomic imprinting, stem cell maintenance and aging [14-16]. The
emerging picture from fundamental research suggests that counteracting PcG repression
can only be achieved by a combination of multiple inputs converging at chromatin [17]. Be‐
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sides the normal requirement for the recruitment of transcription factors and co-activators,
the genomic targets of PcG proteins require the activity of specific demethylases and meth‐
yltransferases for the gene expression to proceed [18].
Importantly for gene therapy, PcG protein complexes have been recently demonstrated to be
able to repress transcription activity in genomic repeats and some transgenes [19].
2.4. Tissue specific and developmental stage specific transcription factors
There are two types of transcription factors: 1) auxiliary proteins, which bind other proteins
in the transcription complex; 2) DNA-binding sequence-specific transcription factors. The
latter type can straightforwardly be recognised in silico by the observation of some distinct
patterns within the DNA-binding domains of transcription factors, e.g. the zinc-finger motif,
the helix-loop-helix motif or the leucine-zipper motif. In silico analysis, e.g. using Biobase
software (http://www.biobase-international.com), is currently also a method of choice for
pinpointing transcription factor binding sites and, therefore, for predicting gene expression
activation patterns.
2.5. Silencing mediated by non-coding RNAs
It has become clear that non-coding RNAs have an important bearing on gene and transgene
expression. In general, there are several mechanisms for the regulatory effects of non-coding
RNAs in gene expression. The two most important control points appear to be the direct
regulation of transcription initiation and the regulation of mRNA degradation through
RNAi by miRNAs. Recent findings revealed that non-coding RNAs are critical factors in the
recruitment of PcG members to the cell chromatin [20,21]. At the same time, the miRNA
pathway turned out to be significant in establishing the DNA methylation and histone mod‐
ification patterns [5,22].
In animals, small RNAs, namely piRNA species, which are typically 24-32 nucleotides in
length, have been shown to mediate genomic DNA methylation. These non-coding RNAs
associate with Piwi clade proteins from the Argonaut superfamily and act analogously to
the well-documented RdMD complexes in plants. The primary role of piRNA in many ani‐
mals appears to be the silencing of retrotransposones via DNA methylation in germ lines. In
fact, the lack of transposons’ suppression in spermatogenesis often results in defects and the
loss of germ cells with age. Although it is not clear whether the same mechanism is respon‐
sible for the protective silencing of viral genomes after viral infections of mammalian cells,
the small RNAs are likely to be involved in de-novo methylation of viral DNA through a sim‐
ilar mechanism. Thus, small noncoding RNAs could potentially provide a flexible regulato‐
ry link between transgene recognition, PcG proteins recruitment and transgene silencing
through DNA methylation, histone modifications and chromatin remodelling.
It appears that, in general, regulation via RNAi has a smaller long-term influence on gene
expression than histone modifications and DNA methylation, acting rather as a rapid re‐
sponse system. Indeed, it would be too energetically inconvenient for cells to synthesize
mRNA and then to destroy it on a permanent basis.
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3. Gene vector properties, which are known to contribute to transgene
silencing
Long-term transgene expression is highly desirable for most gene therapy applications.
However, it is a relatively common occurrence for transgene expression to die out both in
terms of the decrease of the efficiency of expression in individual cells and in terms of the
reduction of the fraction of expressing cells.
A wide variety of vectors can be used for the delivery and establishment of transgenes and
their control elements. Some of the vectors, so called ‘viral vectors’, are generated using a
top-down approach by piggy-backing on the natural gene transfer machinery of viruses. In
contrast, ‘non-viral’ vectors are either pure nucleic acids or synthetic nano-particles, which
are generated using a bottom-up strategy. A pivotal feature of any gene therapy vector
(with the obvious exception of cytoplasmic-only vectors such as mRNA-based vectors) is the
final localization of the delivered transgenes in the nuclei of the target cells. In general,
transgenes can be integrated into random chromosomal sites, integrated into pre-selected
chromosomal sites and/or left to exist episomally. Specialized molecular machinery for effi‐
cient random integration is born by retroviral vectors [23], lentiviral vectors and eukaryotic
transposon vectors. Although the bulk of the DNA delivered with non-transposable plas‐
mid, minicircle and PCR-generated vectors stays episomally, some of the vector DNA also
randomly integrates into the chromosomal DNA. The genetic neighbourhood at a transgene
integration site has an important bearing on the temporal profile of transgene expression.
Nevertheless, many factors that determine the susceptibility of transgene to silencing are de‐
fined by the properties of the employed vector, transgene and co-introduced expression con‐
trol elements.
Multimeric transgene inserts were reported to induce silencing [24]. Unfavourably, even if a
gene vector delivers monomeric DNA, spontaneous chromosomal integrations often result
in vector DNA multimers (it remains unclear whether the multimers are formed before or
after the initial integration event). Silencing due to repetitive DNA was also demonstrated
when the introduced DNA contained trinucleotide repeat expansions [25]. This result has an
implication for the gene therapy of recessive polyglutamine diseases, as therapeutic trans‐
genes can contain triplet expansions of some minimal length. The precise mechanism for si‐
lencing through the recognition of multimeric transgenes and trinucleotide repeats in the
host genomic DNA still remains unclear.
Transgene silencing is often blamed on the malfunction of foreign gene expression control
elements. Indeed, this phenomenon is sometimes referred to as ‘promoter shut down’. Cer‐
tainly, different promoters vary in their ability to maintain long-term transgene expression
in specific cell populations. In particular, there is a clear tendency for some promoters to
turn off in cells where they are not normally active. The mechanisms for such effects can be
quite indirect. Thus, the ubiquitous CMV promoter can activate transgene expression in an‐
tigen-presenting cells with the ensuing immune response and elimination of all vulnerable
transgene expressing cells [26].
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Some bacterial plasmid backbones are known to cause transgene silencing [27-29]. In addi‐
tion, bacterial plasmid backbones interfere with gene delivery into human cells after DNA
administration in vivo because of the innate TLR9-receptor-mediated immune reaction to un‐
methylated bacterial ‘CpG-motifs’ within these backbones. In an attempt to alleviate the im‐
mune reaction, methylation of these sequences in vitro was attempted. Disappointingly, on
some occasions the methylation of plasmid gene vector DNA resulted in increased silencing
of transgene expression [30]. The depletion or ablation of CpG motifs from bacterial plasmid
backbones is known to substantially reduce their immunogenicity. The effects of CpG-de‐
pletion and ablation on transgene silencing are expected, but the available data on this issue
are currently quite limited.
Bacterial lypopolysaccharides (LPS) often co-purify and contaminate plasmid gene vector
DNA. These endotoxins can substantially reduce the efficiency of transfection in vitro [31,32]
and in vivo, where LPS are known to induce a TLR4-receptor-mediated innate immune re‐
sponse. Bacterial endotoxins exhibit a profound effect on cellular regulatory networks [33].
Therefore, it is possible that tilting cells towards ‘transgene-silencing mode’ is an important
contributing factor in the endotoxin-mediated inhibition of transfection.
4. Therapeutic gene vectors and the strategies for their use, which are
employed to avoid transgene silencing
Stable long-term transgene expression depends on the intertwined issues of reliable mainte‐
nance of transgenes in target cells and a robust policy to prevent undesired transgene silenc‐
ing. In general, these two issues are to a large extent under the control of the gene therapist,
as both of them can be addressed through the gene vector design and the delivery mode.
The regulation of gene expression in eukaryotic cells is exceptionally complex and multi-fac‐
eted. As a result, the strategies used to achieve sustainable transgene expression should ad‐
dress multiple possible reasons for the transgene expression shutdown.
4.1. Employment of cytoplasmic-only (non-nuclear) vectors
As most silencing mechanisms are nuclear-based, gene vectors with direct cytoplasmic ex‐
pression, which are not required to enter the nucleoplasm, are well-positioned to avoid si‐
lencing. Thus, non-viral mRNA vectors [34] or positive strand RNA-based viral vectors such
as Sendai virus based vectors [35] can be employed. In addition to the escape from silencing,
the advantages of extra-nuclear-delivery vectors include relatively fast transgene expression
and the absence of potentially mutagenic genomic insertions. The downside is that trans‐
gene expression using such vectors is never long-term because of the eventual degradation
of RNA in cells and because of RNA dilution in the dividing cells. Moreover, the fundamen‐
tally low fidelity of RNA replication undermines efforts to generate artificial vector systems
with replicating RNA episomes. The key upside is that low immunogenicity and minimal
toxicity of such vectors accommodate their repeated administration well.
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4.2. CpG ablation, CpG depletion and minimized DNA vectors
The methylation of chromosomal DNA is one of the most powerful mechanisms for the
shut-down of gene expression. Thus, the design of gene therapy vectors should take into ac‐
count the amenity of the vector sequences to methylation. Firstly, the purposeful exclusion
of entire methylation-prone CpG islands should be considered. Secondly, CpG-depleted or
CpG-ablated modules, produced through the point-wise replacement or removal of CpG di‐
nucleotides, should be taken advantage of. The generation of functionally active CpG-ablat‐
ed sequences is fairly laborious; the CpG-ablated gamma replicon from the bacterial
plasmid R6K and some antibiotic-resistance genes are available from Invivogen.
Clearly, as repetitive sequences are known to induce silencing, their use in therapeutic gene
vectors should be avoided as far as possible.
A common way to reduce the chances of  transgene silencing is  to shorten the auxiliary
vector  sequences  outside  of  the  therapeutic  transgene  expression  cassette.  For  example,
the plasmid selection markers  can be very short  indeed [36].  In  fact,  a  plasmid replica‐
tion  origin  can  be  re-utilised  as  a  plasmid  marker  using  the  ‘plasmid  addiction’  phe‐
nomenon [37].
The trend to exclude unwanted sequences from gene transfer vectors led to the genera‐
tion  of  specialized  minimized  DNA  vectors.  The  most  tested  versions  of  such  vectors
are DNA fragments amplified in vitro  using polymerase chain reaction (PCR) [38],  plas‐
mid-derived linear  terminally looped ‘midges’ [39]  or  circular  supercoiled ‘minicircles’
[40].  Minicircle  vectors  are  produced by intramolecular  site-specific  recombination with‐
in  bacterial  plasmids.  The  superior  efficiency  of  gene  delivery  and  the  longevity  of
transgene  expression  achieved  with  minicircle  DNA  was  observed  in  multiple  studies
(e.g.  [41]).  The  production  of  minimized  DNA  vectors  is  a  biotechnological  challenge.
For example, advanced methods and bacterial strains were developed for efficient bacte‐
ria-based minicircle  DNA production.  The generation of  PCR amplicons  with Taq-poly‐
merase  is  relatively  inexpensive.  However,  the  load  of  Taq-polymerase-introduced
mutations  may  make  one  consider  alternative  in  vitro  amplification  methods  for  the
large-scale synthesis  of  double-stranded DNA, e.g.  ligase chain reaction (LCR),  which is
based on the ligation of preassembled oligonucleotides.
The usual aim in the production of minimized DNA vectors is the removal of sequences of
bacterial origin, such as plasmid backbone sequences, as they can be immunogenic and
some of them were reported to cause silencing [27,29]. It should be emphasized that trans‐
gene silencing through the co-delivery of specific plasmid sequences should not be general‐
ized to all plasmid sequences and each plasmid sequence or bacterial sequence needs to be
tested individually. More research is required to identify the affected bacterial replicons and
to pinpoint the mechanism for the induction of silencing by bacterial DNA sequences. An‐
other avenue is the development of novel specialized forms of minimized vectors, such as
‘minivectors’ for RNAi-based therapy [42].
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4.3. Judicious choice of tissue-specific, inducible and ubiquitous promoters to control
transgene expression
Promoters are the gene expression control elements, which are typically co-introduced with
therapeutic transgenes. In scientific literature, the word ‘promoter’ is often an umbrella
term, which in addition to a minimal promoter also incorporates other linked genetic ele‐
ments such as enhancers, transcription factor binding sites and even regulatory introns. Pro‐
moter is a key element of the regulatory machinery required for long-term non-silenced
transgene expression. Different promoters vary in their strength, tissue specificity, specifici‐
ty for particular developmental stages and ability to react to external stimuli (inducibility).
Each therapeutic setting requires a thoughtful choice of a transgene promoter. Thus, some
ubiquitous promoters are appropriate for consistent long-term transgene expression in dif‐
ferentiating stem cells passing through a number of developmental phases [43]. Ubiquitous
promoters are also appropriate in situations where the resident homologue of the therapeu‐
tic gene is naturally expressed ubiquitously [44]. Tissue-specific promoters have been
known for a long time to be instrumental for long-term transgene expression in terminally
differentiated cells in the liver, vascular tissue, muscle and central nervous system [45]. In‐
ducible promoters are appropriate where the constitutive expression of the therapeutic
transgene is undesired and/or where bespoke activation of the therapeutic transgene is re‐
quired. In addition to the heavily used tetracycline-sensing promoter systems, inducible
promoters can be activated by heat, light and gas-born acetaldehyde [46]. Clearly, the con‐
struction and determined exploitation of new hybrid promoters can resolve many issues in
transgene silencing.
4.4. Multiple transgene insertions into random chromosomal sites
Random integration of transgenes into chromosomes is typical for a number of gene deliv‐
ery systems. Spontaneous chromosomal integration of vector DNA within target cells is not
efficient. Thus, enhanced random chromosomal integration of plasmid gene vectors can be
attained using genetic elements of eukaryotic transposons, retroviruses or lentiviruses (lenti‐
viruses form a subgroup of retroviruses with a somewhat larger genome and the ability to
infect non-dividing cells). However, many integration events occur in unfavourable genetic
neighbourhoods resulting in the silencing of the respective copies of the transgenes. Hence,
position-dependent silencing means that individual transfected or transduced cell clones
differ in terms of the longevity of the transgene expression. Random chromosomal integra‐
tion of transgenes tend to occur in transcriptionally active areas of the genome where heter‐
ochromatin condensation and DNA methylation are unlikely to interfere with transgene
expression. However, as cells differentiate, the pattern of heterochromatization and DNA
methylation changes and some of the transgenes find themselves in transcriptionally silent
areas of the genome. Therefore, the shutdown of transgene expression is particularly com‐
mon in cell populations undergoing differentiation. In these circumstances, it is certainly
possible to increase the chances of long-term transgene expression by increasing the number
of randomly chromosomally integrated transgenes through a higher concentration of vector
and/or repeated rounds of vector administration. Thus, the gene therapist can aim to gener‐
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ate multiple copies of transgenes, indiscriminately integrated within the target genome,
hoping that at least one of the copies will reside in a suitable chromosomal site that will be
immune to silencing.
The employment of transposable genetic elements for efficient random integration of thera‐
peutic transgenes was complicated by the fact that mammals do not have their own active or
easily re-activatable transposons. Therefore, a number of heterologous transposons were
adapted for use in human cells. Recombination machinery from Sleeping Beauty, PiggyBac,
Tol2 and Mos1 transposons was shown to be capable of directing chromosomal integration
of transgenes [47]. Genes for transposases were either included within the cargo gene vector
plasmid or were delivered into human cells on a separate plasmid. Mutant transposases
with enhanced activity for random DNA integration were developed.
A caveat of the anti-silencing strategy relying on multiple transgene insertions into random
chromosome sites is a possibility of potentially deleterious or tumourigenic mutations due
to insertional mutagenesis. However, this drawback is irrelevant for highly differentiated
and non-dividing cells where, firstly, only a limited set of gene products is required for cell
survival and functional competence and, secondly, only a minimal risk is present for the se‐
lection of malignancies. In fact, many terminally differentiated cells are either polyploid or
polynucleated; both of these statuses can alleviate the impact of insertional mutagenesis.
4.5. Site-specific chromosomal integration
One of the ideal scenarios, where transgene silencing is avoided, involves the transgene
DNA being site-specifically integrated into a ‘benign’, silencing-resistant chromosomal site
where there is little chance of transgene consumption by heterochromatin. Thus, targeting
transgenes to a continuously active chromosomal locus can resolve the transgene expression
shutdown problem. In particular, sites could exist within chromosomal DNA, where an inte‐
grated transgene would be immune to chromatin re-arrangements and other regulatory
events during differentiation. A possible candidate site is the human homologue of mouse
Rosa 26 locus, which is being successfully used to express various transgenes in mouse
transgenic studies.
In principle, both transposases and retroviral integrases can be re-engineered into site-di‐
rected recombination enzymes through their fusion with appropriate site-specific ‘tethering’
domains [48]. In addition to tethered transposases and retroviral integrases, the site-specific
integration of transgenes into human chromosomes can be achieved via the modification of
bona fide site-specific recombination systems.
Site-specific DNA recombination systems are comprised of recombinase enzymes, their co-
factors and their cognate recombination sites. Site-specific recombination systems can be
classified into two general types: irreversible and reversible ones.
Site-specific recombination machinery for irreversible recombination is typically borrowed
from the chromosome integration systems of temperate bacteriophages. In integrative re‐
combination systems there are two types of recombination sites, which are normally refer‐
red to as attP and attB. An archetypical example is bacteriophage lambda integrase (Int)
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catalysing a one-off recombination event between the lambda’s attP site and the chromoso‐
mal attB site. The reverse reaction, excision of prophage, is often possible; however, a sepa‐
rate enzyme or a separate subunit of bacteriophage integrase is normally required to
catalyze the excision. The attB sites are typically shorter than the corresponding attP sites.
Thus, in the recombination system from the Streptomyces coelicolor bacteriophage phiC31,
attP is 39 bp long and attB is 34 bp long. Similarly, the recombination system from the Lacto‐
coccus lactis bacteriophage TP901-1 has 50 bp long attP and 31 bp long attB. Consequently, in
artificial recombination systems within the mammalian setting, higher specificity of integra‐
tion is achieved with longer attP sites positioned within the chromosomal loci. It has turned
out that the human genome contains a close analogue of the phiC31 attP site. Extensive mu‐
tagenesis of the phiC31 integrase gene has produced versions of the enzymes with very high
specific activity towards this native human site [49]. Cell-permeable and nuclear targeted
versions of phiC31 integrase were also created, these recombinant enzymes can be used to
create transient, ‘hit-and-run’, recombinase activity in human cells that is required for the
stable integration of therapeutic transgenes.
The typical original in vivo function of the reversible site-specific recombination systems is
to preserve the monomeric status of a plasmid, prophage or episome via the resolution of
circular DNA multimers to monomers; monomeric status is important for the maintenance
stability of many plasmid replicons. Commonly used reversible systems include bacterio‐
phage’s P1Cre recombinase with its cognate loxP sites and FLP recombinase (flipase) with its
cognate FTR sites from the yeast Saccharomyces cerevisiae ‘2-micron circle’ episome. Many re‐
versible systems were successfully used for the chromosomal integration of transgenes in
pre-engineered cells. However, it should be noted that some site-specific recombination sys‐
tems are fundamentally unsuitable for chromosomal integration strategies. Thus, ParA re‐
solvase and MRS sites from the plasmid RK2 constitute a reversible system for
intramolecular recombination; however, in this system there is no molecular recombination
between MRS sites situated on separate DNA molecules.
Of course, the employed bacterial recombination systems have to be functional in eukaryotic
cells [50]. A potential pitfall to be aware of is that some of the site-specific recombinases re‐
quire an additional co-factor; e.g., IHF (integration host factor) is an obligatory element for
lambda Int/attB/attP system. Unexpectedly and encouragingly, at least on some occasions
mammalian cells are able to provide suitable co-factors [50].
The wild type human adeno-associated virus type 2 (AAV2) is the only known human virus
capable of site-specific chromosomal integration. AAV2 uses the chromosome-tethering
strategy for genomic insertions. Expression of the Rep gene is required for integration of the
viral genome into a unique DNA sequence within specific chromosomal loci. The Rep pro‐
teins of this virus bind both several Rep Binding Sites (RBS) within the viral DNA and the
RBS sites in the human genome (known as AAVS1, AAVS2 and AAVS3) leading to prefer‐
ential integration of the viral DNA in the genomic loci 19q13.42, 5p13.3 and 3p24.3.
An important step forward in the exploitation of the site-specific integration system of AAV
was achieved when the AAV Rep protein was used to direct the integration of integrase-de‐
fective retroviral vectors into human 19q13.42 locus [51]. The transfer of the locus-specific
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chromosomal integration apparatus of AAV2 to other vector types, e.g., plasmid gene vec‐
tors, can be accomplished as well [52].
4.6. Episomal localisation of a transgene
Episomal maintenance of transgene expression cassettes is an attractive strategy to escape
the control of some resident gene regulation systems, such as chromatin remodelling machi‐
nery, over transgene expression. The problem with this approach is that viral replicons, e.g.,
compact episomal replicons from SV40, polyoma, papilloma viruses, which are often com‐
pletely adequate for the research use of gene vectors, are rarely acceptable for therapeutic
applications. Indeed, the expression of the large SV40 T-antigen and, hence, the malignant
transformation of the recipient host cells is required for SV40-origin-based replication. Simi‐
larly, EBNA1-oriP DNA segment of Epstein-Barr Virus (EBV) can be used to support the
maintenance of plasmid gene vectors in the nucleoplasm of dividing laboratory cells. Al‐
though EBNA1 expression does not result in a typical malignant transformation, it can still
tilt the cells towards undesired immortalisation [53].
Alternative  benign  episomal  replicons  are  being  sought.  Encouragingly,  the  scaffold/
matrix  attachment  region  (S/MAR)  from  the  human  β-interferon  gene  was  reported  to
support non-viral episomal replication when coupled to a promoter [54]. Thus, episomal
maintenance  mediated  by  S/MAR  elements  might  be  the  reason  behind  the  well-estab‐
lished  beneficial  effects  of  these  elements  on  transgene  expression  [41,55,56].  Non-viral
episomal vectors also include mammalian artificial  chromosomes (MACs),  which can be
generated through both  top-down and bottom-up approaches  [57,58].  However,  current
progress  with MACs is  limited because of  prohibiting costs  associated with the genera‐
tion of these vectors.
4.7. Employment of the locus control regions within the vectors
Protection of integrated transgenes from encroaching heterochromatin can be achieved with
chromatin insulators or other cis-acting locus control regions (LCRs) [59]. The mechanistic
details of LCRs action are currently not clear and so the terminology in this area is some‐
what diffuse with, for example, ‘chromatin boundary elements’ and ‘chromatin insulators’
often being used synonymously [60,61]. Some enhancers have an important bearing on the
state of chromatin and, therefore, can also be viewed as LCRs. Experiments with some
known chromatin insulators show that their effects on transgene expression are not always
positive and to a large extent depend on the cell context [62,63]. Nuclear ‘matrix attachment
region’ elements (MARs) and the effectively synonymous nuclear ‘scaffold attachment re‐
gion’ elements (SARs) are known to possess some LCR activity. Some authors are trying to
avoid the confusion between MARs and SARs using the joined names ‘SAR/MARs’, ‘MAR/
SARs’ or ‘S/MARs’. Promising results in terms of sustained transgene expression were ach‐
ieved with MARs both within the scenario where two MAR elements are used ‘to protect the
transgene from the flanks’ [64,65] and the scenario where a single promoter-MAR couple is
driving the transgene’s episomal replication [41].
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4.8. Top-up transgene administration to compensate for silenced transgenes
Normally, if the expression of therapeutic transgenes did die out, it is possible to perform a
new round of gene transfer, thus achieving a new burst of transgene expression. Repeated
vector administration can be particularly sought-after when the target cell population expe‐
riences programmed death, while the respective progenitor cell pool is poorly accessible for
therapeutic gene transfer. This strategy can be used without hesitation in an ex vivo gene
therapy setting where therapeutic genes are delivered in vitro to dividing cells derived from
a patient’s biopsy prior to autologous transplantation. In contrast, in an in vivo gene therapy
setting, the drawbacks of vector re-administration include not only the increased complexity
and cost of treatment, but also the realistic possibilities that immunity to elements of the
vector might develop and that the effects of the toxic elements of the vector might build up
to an unacceptable level. That is why low immunogenicity, low toxicity and the biodegrada‐
bility of auxiliary vector elements are important in the vector re-administration treatment
format.
4.9. Selection of clones with stable non-silenced transgene expression
Reliable, robust and error-free site-specific integration into mammalian cells lacking pre-en‐
gineered integration sites is difficult to achieve. Simpler alternatives for attaining stable
long-term transgene expression exist in the ex vivo gene therapy approach. In one of the
treatment scenarios, transgenes are integrated randomly, e.g. using lentiviral vectors or nak‐
ed DNA vectors. It is then possible to select the best clone with minimal initial transgene
silencing and minimal propensity for transgene expression shutdown among a heterogene‐
ous population of transfected or transduced cells. The preferred method for cell selection is
antibody-based magnetic sorting, as this method allows processing of large numbers of cells
without recourse to heterologous fluorescent proteins and mutagenic UV irradiation as in
fluorescence activated cell sorting (FACS). Clearly, such a clone pre-selection strategy can be
used in conjunction with some other counter-silencing strategies (e.g. multiple random
transgene insertions or top-up transgene administrations).
4.10. Small molecule enhancers of transgene expression
It is extremely attractive to use small molecule compounds to counteract transgene silenc‐
ing. Substances known to influence chromatin’s state are prime candidates for this role.
Thus, histon deacetylase inhibitors Trichostatin A, 4-phenylbutyric acid, butyric acid, valeric
acid and caproic acid were successfully used to enhance transgene expression after transient
trasfection [66]. Available data indicate that another histone deacetylase inhibitor, valproic
acid, and also retinoic acid, which is known to act through a receptor-mediated mechanism,
are epigenetically active substances and, therefore, in certain situations could be considered
for use as transgene expression stimulants. Some small molecule enhancers could be specific
for particular vectors used for gene transfer. Thus, hydroxyurea is known to boost transgene
expression after delivery with AAV vectors [67]. In this case, transgene expression is likely
to be spurred not through the inhibition of standard silencing mechanisms but rather
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through the more active synthesis of the second DNA strand in the delivered single-strand‐
ed AAV vector DNA [67].
4.11. Selection of low immunogenic vectors and transgene products
The elimination of therapeutic gene vectors and transgenic cells by the immune system can
imitate the silencing of transgene expression. Thus, the employment of low-immunogenic
vectors is a preferred option. Vectors’ epitopes should mimic the native epitopes of individ‐
ual patients and do not match their pre-existing immune profile. Coating vector particles
with immunologically inert polymers like polyethyleneglycol is one of the strategies to es‐
cape immune surveillance. Alternatively, vector particles can be developed, which are able
to mimic the immune-evasion strategy of some viruses that are capable of ‘hiding’ at the cell
surface [68]. Non-immunogenic transgene products, e.g. exclusively human versions of pro‐
teins, should be chosen to prevent cell elimination via immune reactions in vivo. If required,
transgene products should be re-engineered to achieve the ‘stealth effect’ and to tailor them
to the immunological profiles of individual patients.
5. Conclusion
Epigenetic control by the target cells can result in permanent transgene silencing or in the
instability of transgene expression. Thus, one needs to pursue therapeutic strategies, which
can achieve long-term transgene expression by taking advantage of, circumventing or over‐
riding silencing favouritism of the resident gene expression control mechanisms.
There are many levels at  which the longevity of  transgene expression can be addressed
through  the  gene  vector  choice,  design  and  administration  regimen,  including:  1)  em‐
ployment  of  non-nuclear  vectors,  e.g.  mRNA  or  Sendai  virus  based  vectors;  2)  control
of transgene modules’ amenity to methylation (e.g. purposeful exclusion of methylation-
prone CpG islands);  3) employment of minimised DNA vectors such as minicircle DNA
to avoid transgene silencing by the bacterial portion of the plasmid vectors; 4) choice of
a suitable promoter-enhancer combination with the judicious use of tissue specific, indu‐
cible  and  ubiquitous  promoters;  5)  achieving  a  high  number  of  randomly  integrated
transgenes;  6)  control  of  the  chromosomal  integration  sites  via  artificial  site-preferences
of  retroviral  integrases,  transposases  or  via  harnessing  of  site-specific  integration  sys‐
tems;  7)  localisation of  transgenes  on nuclear  episomes;  8)  chromatin  re-modelling  con‐
trol  via  cis-acting  elements  such  as  insulator  elements  and  other  LCRs;  9)  repeated
vector  administration;  10)  selection  of  individual  cell  clones  with  transgenes  integrated
into favourable loci;  11) use of chemical reagents influencing the epigenetic state to ach‐
ieve  higher  and  more  long-term  transgene  expression;  and  12)  choice  of  non-immuno‐
genic  transgene  products  to  prevent  the  elimination  of  transgenic  cells  via  immune
reactions in vivo.
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Clearly, the future solutions to transgene silencing enabling stable long-term expression of
therapeutic transgenes will depend on the determined implementation of the above strat‐
egies and their effective combinations.
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